HGSI Insider Trading Activity and SEC Form 4 Filings
HGSI insider trading summary
No open-market insider purchases or sales of Human Genome Sciences Inc (HGSI) have been reported on SEC Form 4 in the past 12 months.
Latest HGSI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 2, 2012 | Glaxosmithkline PLC | Director | Buy | $844.1M (59,232,487 @ $14.25) |
| Aug 2, 2012 | Glaxosmithkline PLC | Director | Buy | $48.6M (3,413,699 @ $14.25) |
| Aug 1, 2012 | Glaxosmithkline PLC | Director | Buy | $25.5M (1,788,186 @ $14.25) |
| Aug 1, 2012 | Glaxosmithkline PLC | Director | Buy | $81.0M (5,686,715 @ $14.25) |
| Jul 30, 2012 | Glaxosmithkline PLC | Director | Buy | $70.3M (4,934,743 @ $14.25) |
| Aug 5, 2011 | Ngoc Tuan Ha | Director | Buy | $160K (10,000 @ $16.00) |
| Aug 5, 2011 | George J Morrow | Director | Buy | $158K (10,000 @ $15.79) |
| Aug 4, 2011 | Colin Goddard | Director | Buy | $49K (3,000 @ $16.17) |
| Jun 1, 2011 | Curran Simpson | Sr. VP, Operations | Sell | $621K (22,904 @ $27.11) |
| May 2, 2011 | Barry Labinger | Exec VP & CCO | Sell | $220K (7,347 @ $30.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.